Abbott Labs Stock Rises After $385 Million DOJ Settlement on Infant Formula

Shares of Abbott Laboratories (ABT) gained on Tuesday after the company reached a $385 million settlement with the U.S. Department of Justice. The agreement resolves allegations under the False Claims Act concerning powdered infant formula, providing investors with clarity on a long-standing legal issue.

Details of the Agreement

The settlement addresses claims related to infant formula produced at Abbott's facilities in Sturgis, Michigan, and Casa Grande, Arizona, between 2018 and 2022. According to the announcement, the deal allocates approximately $348.7 million to the federal government and $36.3 million to certain states to resolve Medicaid-related claims.

A crucial detail for investors is that the agreement includes no finding of fault or liability on Abbott's part. This clause suggests a clean resolution rather than an admission of wrongdoing, which the market has interpreted positively.

Ad

Market Reaction and Outlook

Abbott's stock rose 1.2% in midday trading, reaching an intraday high of $104.44. The move was a company-specific catalyst, standing in contrast to a weaker overall market, with the S&P 500 and Nasdaq Composite both trading down approximately 0.3%.

For investors, the settlement quantifies a significant financial liability and removes a legal overhang that had weighed on sentiment. By resolving the investigation without admitting fault, Abbott can move forward with a clearer outlook, allowing the market to refocus on the company's operational performance ahead of its next earnings report, scheduled for mid-October.